
Filed by OncoGenex Pharmaceuticals, Inc.
Pursuant to Rule 425 under the Securities Act of 1933
Deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934

Subject Company: OncoGenex Pharmaceuticals, Inc. Commission File No.: 033-80623

On February 21, 2017, OncoGenex Pharmaceuticals, Inc. provided copies of the following posters to investors:

PACIFIC Trial: A Randomized Phase II Study of Apatorsen and Abiraterone in Patients with Metastatic CRPC Who Have Had PSA Progression While Receiving Abiraterone







Borealis-2: A randomized phase II study of OGX-427 (apatorsen) plus docetaxel versus docetaxel alone in

platinum-resistant metastatic urothelial cancer (mUC)
out, R. Alter, A. Balar, J. Hoffmacheniat, P. Girsar, R. Lauer, E. Gausollin, C. Homes, G. Sonowide, C. Alban

hoosier. NCT 01780545

ABSTRACT #289






24.8% 34.7% 20.8% 51.5%



28.3% 34.3% 19.2% 56.6%


Table 1. Baseline characteristics






(occurring in ≥3% of patients)	Docetaxel + Apatorsen		Docetaxel		
	N	*	N	*	
Neutropenia	33	35.1	29	30.3	
Anemia	16	17.2	12	12.5	
Sepsis	14	15.1	8	8.3	
Urinary tract infections (UTI)	13	13.8	7	7.3	
Febrile neutropenia	10	10.6	8	8.3	
Lymphopenia	11	11.8	7	7.3	
Diarrhea	7	7.5	5	5.2	
Hypertension		4.3	8	8,3	
Dyspnea	6	6.4	4	4.1	
General muscle weakness	- 4	43	140	43	
Verniting	4	4.3	3	3.1	
Thromboembolic events	2	2.1	5	52	
Safety constation	91	100	96	100	

Figure 2. Kaplan-Meier estimate of OS according to Stratification Factors and treatment ass





dmark Analysis for Changes in serum Hsp27 levels Do OS from end of Cycle 2 for treatment effect

% change in Hsp27* from baseline to Cycle 2	Treatment Assignment	N	Deaths.	Median survival (mos)	HR	R0%CL	Upper 80%CL	action P
Decreased or	DOC+apatorsen	22	14	12.2	0.29	0.18	0.48	0.073
520.6% increase from baseline	DOC	18	18	5.1				
>20.6% increased from baseline	DOC+spatomen	18	- 11	7.9	0.77	0.46	1.30	
	DOC	22	16	6.8				

* Median % change in serum Hsp27 levels from baseline to the end of Cycle 2 was a 20.5% increase in Hsp27 levels

CONCLUSIONS

- In this randomized phase 2 trial, docetaxel administered with apatorsen (OGX-427) was well tolerated and provided a survival benefit compared to docetaxel alone for patients with metastatic UC that are relapsed/refractory after receiving a platinum-containing regimen

 Survival benefit was numerically more apparent in patients treated with apatorsen who have 1 or more Belimunt risk factors

 Higher baseline serum Hsp27 levels appear to be an independent prognostic indicator for shorter survival outcomes

 Further studies are warranted evaluating the potential of apatorsen to improve survival in patients being treated with metastatic UC